Evidence map›Paper›PMID 36207657›Full record

ArticleDrug delivery and translational research2023

Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins.

Bettina Gabold, Friederike Adams, Sophie Brameyer, Kirsten Jung, Christian L Ried, Thomas Merdan, Olivia M Merkel

Abstract read
In one paragraph

Article in Drug delivery and translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bettina GaboldDepartment of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians Universität München, 81377, Munich, Germany.
Friederike AdamsInstitute of Polymer Chemistry, Chair of Macromolecular Materials and Fiber Chemistry, University of Stuttgart, Stuttgart, Germany.
Sophie BrameyerDepartment of Biology I, Microbiology, Ludwig-Maximilians-Universität München, Martinsried, Germany.
Kirsten JungDepartment of Biology I, Microbiology, Ludwig-Maximilians-Universität München, Martinsried, Germany.
Christian L RiedDrug Product Development, AbbVie Deutschland GmbH, Ludwigshafen, Germany.
Thomas MerdanDrug Product Development, AbbVie Deutschland GmbH, Ludwigshafen, Germany.
Olivia M MerkelDepartment of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians Universität München, 81377, Munich, Germany. olivia.merkel@lmu.de.ORCID 0000-0002-4151-3916

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nose-to-brain delivery presents a promising alternative route compared to classical blood-brain barrier passage, especially for the delivery of high molecular weight drugs. In general, macromolecules are rapidly degraded in physiological environment. Therefore, nanoparticulate systems can be used to protect biomolecules from premature degradation. Furthermore, targeting ligands on the surface of nanoparticles are able to improve bioavailability by enhancing cellular uptake due to specific binding and longer residence time. In this work, transferrin-decorated chitosan nanoparticles are used to evaluate the passage of a model protein through the nasal epithelial barrier in vitro. It was demonstrated that strain-promoted azide-alkyne cycloaddition reaction can be utilized to attach a functional group to both transferrin and chitosan enabling a rapid covalent surface-conjugation under mild reaction conditions after chitosan nanoparticle preparation. The intactness of transferrin and its binding efficiency were confirmed via SDS-PAGE and SPR measurements. Resulting transferrin-decorated nanoparticles exhibited a size of about 110-150 nm with a positive surface potential. Nanoparticles with the highest amount of surface bound targeting ligand also displayed the highest cellular uptake into a human nasal epithelial cell line (RPMI 2650). In an air-liquid interface co-culture model with glioblastoma cells (U87), transferrin-decorated nanoparticles showed a faster passage through the epithelial cell layer as well as increased cellular uptake into glioblastoma cells. These findings demonstrate the beneficial characteristics of a specific targeting ligand. With this chemical and technological formulation concept, a variety of targeting ligands can be attached to the surface after nanoparticle formation while maintaining cargo integrity.

Indexed as

ChitosanGlioblastomaNanoparticlesBrainDrug Delivery SystemsHumansLigandsTransferrinChitosanLigandsTransferrinBrain deliveryChitosan nanoparticlesGlioblastomaNose-to-brainTransferrin receptor

Identifiers

PMID36207657
PMCPMC9892103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.